DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Lastacaft is a drug marketed by Allergan and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has forty-six patent family members in thirty countries.
The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alcaftadine profile page.
Lastacaft was eligible for patent challenges on July 28, 2014.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 19, 2027. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for LASTACAFT
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||57|
|Drug Prices:||Drug price information for LASTACAFT|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for LASTACAFT|
|What excipients (inactive ingredients) are in LASTACAFT?||LASTACAFT excipients list|
|DailyMed Link:||LASTACAFT at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for LASTACAFT
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LASTACAFT
Identify potential brand extensions & 505(b)(2) entrants
|ORA, Inc.||Phase 4|
|Starx Research Center, LLC||Phase 4|
Pharmacology for LASTACAFT
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Allergan||LASTACAFT||alcaftadine||SOLUTION/DROPS;OPHTHALMIC||022134-001||Jul 28, 2010||RX||Yes||Yes||Get Started Free||Get Started Free||Get Started Free|
|Allergan||LASTACAFT||alcaftadine||SOLUTION/DROPS;OPHTHALMIC||022134-001||Jul 28, 2010||RX||Yes||Yes||Get Started Free||Get Started Free||Y||Get Started Free|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Patent No.||Patent Expiration|
|Allergan||LASTACAFT||alcaftadine||SOLUTION/DROPS;OPHTHALMIC||022134-001||Jul 28, 2010||Get Started Free||Get Started Free|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>Patent No.||>Patent Expiration|
|Country||Patent Number||Estimated Expiration|
|Taiwan||I450721||Get Started Free|
|New Zealand||571690||Get Started Free|
|European Patent Office||3150209||Get Started Free|
|Ireland||921918||Get Started Free|
|Hong Kong||1131331||Get Started Free|
|Poland||2004196||Get Started Free|
|>Country||>Patent Number||>Estimated Expiration|